/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. OncLive® On Air
  2. S19 Ep9: Biology-Driven Care and AI Tools Steer the Future of Breast Oncology
S19 Ep9: Biology-Driven Care and AI Tools Steer the Future of Breast Oncology

S19 Ep9: Biology-Driven Care and AI Tools Steer the Future of Breast Oncology

OncLive® On Air · Oct 15, 2026

Dr. Jamie Abraham outlines how biology-driven care, novel ADCs, and clinician-guided AI tools are transforming breast oncology standards.

Genomic Recurrence Scores Outweigh High-Risk Anatomical Factors When De-Escalating Breast Cancer Chemotherapy

In the phase III OPTIMA trial, patients with high-risk anatomical features like node positivity and large tumors did not benefit from adding chemotherapy to endocrine therapy if their genomic score was low. Invasive breast cancer-free survival was identical between chemo and endocrine-only arms for patients with scores under 60.

S19 Ep9: Biology-Driven Care and AI Tools Steer the Future of Breast Oncology thumbnail

S19 Ep9: Biology-Driven Care and AI Tools Steer the Future of Breast Oncology

OncLive® On Air·a month ago

Post-Neoadjuvant Trastuzumab Deruxtecan Requires Aggressive Interstitial Lung Disease Monitoring Despite Radiation Compatibility

DESTINY-Breast05 demonstrated a 53% improvement in invasive disease-free survival over T-DM1, but exhibited a 9.6% interstitial lung disease rate, including two fatal cases. Dr. Abraham noted concurrent radiation does not elevate this risk, making early symptom recognition and rapid steroid intervention critical.

S19 Ep9: Biology-Driven Care and AI Tools Steer the Future of Breast Oncology thumbnail

S19 Ep9: Biology-Driven Care and AI Tools Steer the Future of Breast Oncology

OncLive® On Air·a month ago

Day-Eight Growth Factor Support and Dose Tailoring Mitigate Sacituzumab Govitecan Cytopenias

Patients receiving sacituzumab govitecan frequently face neutropenia and diarrhea, especially when heavily pretreated. Dr. Abraham recommends initiating treatment at the full 10 mg/kg dose on days one and eight, followed by dose reductions to 7.5 mg/kg or day-eight Neulastra administration to allow one recovery week.

S19 Ep9: Biology-Driven Care and AI Tools Steer the Future of Breast Oncology thumbnail

S19 Ep9: Biology-Driven Care and AI Tools Steer the Future of Breast Oncology

OncLive® On Air·a month ago

Clinicians Must Directly Shape AI Tools to Prevent Non-Medical Developers From Dictating Oncology Care

Dr. Abraham stresses that physicians, nurses, APPs, and pharmacists must actively engage in developing artificial intelligence rather than letting outside technologists dictate healthcare tools. Without clinical voices steering adoption, external developers could implement systems without understanding patient-centered safety, trust, and practical clinical care.

S19 Ep9: Biology-Driven Care and AI Tools Steer the Future of Breast Oncology thumbnail

S19 Ep9: Biology-Driven Care and AI Tools Steer the Future of Breast Oncology

OncLive® On Air·a month ago

Clinical AI Platforms Synthesize Cross-Tumor Evidence for General Community Oncologists Treating Diverse Cancers

While academic specialists focus entirely on single diseases, community oncologists treat approximately 70% of cancer patients across constantly shifting malignancies. AI search and summary tools help general oncologists rapidly digest complex literature and filter the explosion of trial data between seeing patients with diverse diagnoses.

S19 Ep9: Biology-Driven Care and AI Tools Steer the Future of Breast Oncology thumbnail

S19 Ep9: Biology-Driven Care and AI Tools Steer the Future of Breast Oncology

OncLive® On Air·a month ago